Ejner Jensen
Director/Board Member at Enduro Genetics ApS
Profile
Ejner Bech Jensen is currently the Director at Enduro Genetics ApS.
Previously, he worked as the Director of Molecular Biotechnology at Novo Nordisk A and Adenium Biotech ApS.
He also served as the Vice President of Molecular Biotechnology at Novozymes A from 2013 to 2014.
Before that, he was a Principal at Nordisk Gentofte A.
Ejner Jensen active positions
Companies | Position | Start |
---|---|---|
Enduro Genetics ApS
Enduro Genetics ApS Miscellaneous Commercial ServicesCommercial Services Enduro Genetics ApS is a Danish biotechnology research company that specializes in developing bio products. The company is based in Copenhagen, Denmark. Enduro Genetics was founded by Peter Rugbjerg and Christian Munck. The CEO is Christian Munch. | Director/Board Member | - |
Former positions of Ejner Jensen
Companies | Position | End |
---|---|---|
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | Chief Tech/Sci/R&D Officer | - |
NOVO NORDISK A/S | Corporate Officer/Principal | - |
Nordisk Gentofte A/S | Corporate Officer/Principal | - |
Adenium Biotech ApS
Adenium Biotech ApS Pharmaceuticals: MajorHealth Technology Adenium Biotech ApS develops and commercializes novel antibiotics for the treatment of multi drug resistant bacterial infections. It focuses on treatment of nosocomial infections, in particular complicated urinary tract infections and hospital or ventilator acquired pneumonia caused by multi drug resistant Gram-negative bacteria. The company offers Arenicin, an anti-microbial peptide against gram-negative pathogens for pneumonia, urinary tract infection, and acinetobacter baumanii. Adenium Biotech was founded by Peter Nordkild on August 24, 2011 and is headquartered in Copenhagen, Denmark. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
NOVO NORDISK A/S | Health Technology |
Private companies | 4 |
---|---|
Adenium Biotech ApS
Adenium Biotech ApS Pharmaceuticals: MajorHealth Technology Adenium Biotech ApS develops and commercializes novel antibiotics for the treatment of multi drug resistant bacterial infections. It focuses on treatment of nosocomial infections, in particular complicated urinary tract infections and hospital or ventilator acquired pneumonia caused by multi drug resistant Gram-negative bacteria. The company offers Arenicin, an anti-microbial peptide against gram-negative pathogens for pneumonia, urinary tract infection, and acinetobacter baumanii. Adenium Biotech was founded by Peter Nordkild on August 24, 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
Nordisk Gentofte A/S | |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | Process Industries |
Enduro Genetics ApS
Enduro Genetics ApS Miscellaneous Commercial ServicesCommercial Services Enduro Genetics ApS is a Danish biotechnology research company that specializes in developing bio products. The company is based in Copenhagen, Denmark. Enduro Genetics was founded by Peter Rugbjerg and Christian Munck. The CEO is Christian Munch. | Commercial Services |
- Stock Market
- Insiders
- Ejner Jensen